Dementia Treatment Market Revenue to Attain USD 37.55 Bn by 2033
Published: 27 Nov 2025
Author: Precedence Research
Dementia Treatment Market Revenue and Trends 2025 to 2033
The global dementia treatment market revenue is valued at USD 19.98 billion in 2025 and is expected to attain around USD 37.55 billion by 2033, growing at a CAGR of 8.21 % during forecast period. This market is experiencing growth, driven by the rising awareness and diagnosis rates of dementia and supportive government policies.
What Are the Factors That Have a Significant Contribution to the Growth of the Dementia Treatment Market?
The growing patient awareness, increasing adoption of advanced treatment methodologies, improved diagnostic capabilities, and rising private and government funding for R&D are expected to drive the growth of the dementia treatment market during the forecast period. Health systems across regions are investing in biomarker testing, neuroimaging tools, and digital cognitive assessment platforms, which support earlier diagnosis and improve monitoring of disease progression. The market’s growth is primarily driven by the rising prevalence of dementia, particularly among older adults.
The older adults are more susceptible to dementia, which creates a substantial and growing need for effective dementia treatment. As life expectancy increases in both high-income and middle-income countries, the global population aged 65 and above continues to expand. As the number of individuals aged above 65 is rising, the number of dementia patients is projected to increase to 131.5 million by the year 2050, reflecting the global demographic shift toward aging populations documented in long-term epidemiological forecasts.
According to the data published by the World Health Organization in March 2025, 57 million people had dementia worldwide in 2021, over 60 percent of whom live in low and middle-income countries. Every year, there are nearly 10 million new cases. Several risk factors have been identified for dementia, including being above the age of 65, such as hypertension, diabetes, smoking, and depression. These factors make it more likely for older adults to develop dementia, especially when combined with limited access to preventive care.
With the growing population of individuals over 65, the number of dementia patients is expected to increase in the coming years. The prevalence of dementia has been associated with socioeconomic level and culture, with higher burdens recorded in regions that experience healthcare inequality, lower education levels, and reduced access to early screening and long-term care services.
Segment Insights
- By dementia type, the Alzheimer’s Disease segment held a dominant market share in the dementia treatment market. Alzheimer's disease (AD) accounts for the vast majority of dementia cases, nearly 60 to 70%.
- By treatment type, the pharmacological therapies segment held the largest market share in 2024. The segment's growth is primarily driven by the growing shift toward novel disease-modifying therapies (DMTs).
- By product type, the prescription drugs segment held the largest share in the dementia treatment market in 2024, owing to the increasing demand for Cholinesterase Inhibitors, NMDA Receptor Antagonists, and Disease-Modifying Therapies (DMTs) as first-line treatments for dementia.
- By end-user, the hospitals & neurology clinics segment held the largest market share of 40% in 2024, owing to the increasing need for specialized care, comprehensive diagnostic and monitoring infrastructure, and multidisciplinary teams such as neurologists, psychiatrists, and pharmacists for holistic patient care.
Regional Insights
The North America region dominates the global dementia treatment market. The region has an advanced healthcare infrastructure that facilitates high rates of diagnosis and the effective delivery of complex and novel dementia treatment. Factors such as rising regulatory approvals, high per capita healthcare spending, a surge in R&D investment, improved diagnostic capabilities, an aging population, and the increasing prevalence of Alzheimer's disease are anticipated to contribute significantly to the growth of the dementia treatment market. In addition, the increasing presence of hospitals & neurology clinics as the primary point of diagnosis and effective treatment initiation for dementia patients, particularly for complex or advanced therapeutic interventions.
In February 2024, the U.S. Food and Drug Administration announced the approval of Kisunla (donanemab-azbt) injection for the treatment of Alzheimer’s disease. Treatment with Kisunla should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was studied in the clinical trials.
On the other hand, the Asia Pacific region is anticipated to grow at the fastest rate in the market during the forecast period. The growth of the region is driven by a large aging population, developing healthcare infrastructure, favorable government regulations, increasing patient awareness and access to diagnostic tools, and the rising incidence of dementia.
Moreover, significant investment in R&D by key players and the increasing introduction of new therapeutic products are driving market expansion in the coming years. For instance, in December 2023, Ono Pharmaceutical Co., Ltd. announced that it had entered into a research collaboration agreement with the UK Dementia Research Institute, a national institute dedicated to dementia research, to identify novel therapeutic targets in the field of dementia. As part of our ongoing open innovation, Ono will initiate a multi-year collaborative research project with the UK Dementia Research Institute to identify novel therapeutic targets for the diagnosis, prevention, and treatment of dementia.
Dementia Treatment Market Coverage
| Report Attribute | Key Statistics |
| Market Revenue in 2025 | USD 19.98 Billion |
| Market Revenue by 2033 | USD 37.55 Billion |
| CAGR from 2025 to 2033 | 8.21% |
| Quantitative Units | Revenue in USD million/billion, Volume in units |
| Largest Market | North America |
| Base Year | 2024 |
| Regions Covered | North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa |
Recent Developments
- In October 2025, Brain health and dementia care pioneer Isaac Health announced its listing on LillyDirect to expand access to pivotal Alzheimer’s disease care. LillyDirect is an online platform launched by pharmaceutical giant Eli Lilly to provide consumers with a holistic, curated digital health experience. (Source: https://www.forbes.com)
Get this report to explore global market size, share, CAGR, and trends, featuring detailed segmental analysis and an insightful competitive landscape overview @ https://www.precedenceresearch.com/sample/7140
You can place an order or ask any questions, please feel free to contact us at sales@precedenceresearch.com |+1 804 441 9344